Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Trial Profile

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs GEN 009 (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Genocea Biosciences
  • Most Recent Events

    • 02 Jan 2019 According to a Genocea Biosciences media release, enrollment of patients in the first part of the clinical trial has been completed and the first patient has been dosed in the trial. The company expects to report top-line results from this part of the study late in the second quarter of this year or early in the third quarter.
    • 01 Nov 2018 According to a Genocea Biosciences media release, immunogenicity data are expected in the first half of 2019.
    • 09 Oct 2018 According to a Genocea Biosciences media release, data from this study will be presented at the upcoming 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top